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Abstract
In humans, at least six members of the multidrug resistance-associated protein (MRP) family are thought to exist. Here we
report the molecular cloning of two splice variants of MRP3 from human liver. In addition, MRP3 genomic organization
including the 5P-flanking region and a major portion of the MRP3 intron-exon organization are identified and
characterized. ß 1999 Published by Elsevier Science B.V. All rights reserved.
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Multidrug resistance (MDR) to a variety of struc-
turally unrelated cancer chemotherapeutic agents
often results in cancer treatment failure. In vitro
data indicate that one important mechanism for
this phenomenon is the reduction in intracellular
drug concentration, mediated by the expression of
ATP-dependent e¥ux transporters, such as P-glyco-
protein and members of the MRP (multidrug resist-
ance-associated protein) transporter family [1,2].
MRP1, for example, has been shown to transport a
wide range of glutathione, glucuronide, and sulfate
drug conjugates [3]. MRP1, MRP2 (also known as
cMOAT) and P-glycoprotein are expressed not only
in tumors, but also in normal tissues (e.g. kidney,
intestinal mucosa) and can thereby determine the
disposition of xenobiotics and endogenous com-
pounds (e.g. anticancer agents, HIV protease inhib-
itors, digoxin and cysteinyl leukotrienes [4^6]). Anal-
ysis of Expressed Sequence Tag (EST) cDNA
database had previously identi¢ed partial cDNA
clones named MRP3 to MRP6 ([7] and GenBank
No. U91318). More recently, MRP3, and MRP4
(also termed MOAT-B) full-length cDNAs were
identi¢ed [8,9]. In this report we describe, for the ¢rst
time, the cloning of two alternative splice variants of
human MRP3 cDNA and its genomic organization,
including the 5P-£anking region and a major portion
of the exon-intron boundaries.
Initial MRP3 sequence information was obtained
by screening the EST database library for MRP1
homologs. Brie£y, a computer-based (BLAST, NCI,
0005-2736 / 99 / $ ^ see front matter ß 1999 Published by Elsevier Science B.V. All rights reserved.
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Bethesda, MD) homology screening of EST database
using the full-length MRP1 cDNA sequence as a
template was carried out. An EST clone (No.
84966) was identi¢ed as a potential candidate. This
clone was then obtained from Research Genetics
(Huntsville, AL). Sequencing revealed the clone to
be approx. 2.0 kb in length, encompassing the com-
plete 3P terminus of MRP3. Using this sequence in-
formation, PCR was carried out on a Vgt11-based
human liver cDNA library (kindly provided by Dr.
F. Gonzalez, NIH, Bethesda, MD) using oligonu-
cleotide primers speci¢c to the V phage arm (5P-
GGTGGCGACGACTCCTGGAGCC-3P), and an
antisense primer speci¢c to MRP3 (5P-ACC-
GGTTGGAGATGATGTAGGGGTAGCAGC-3P,
position 3551 of MRP3 coding sequence). This re-
Fig. 1. Amino acid sequences encoded by human MRP3 and the splice variants MRP3A and MRP3B. Potential transmembrane re-
gions are underlined [11]. The Walker A, B, and C motifs of the putative nucleotide binding domains are boxed.
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sulted in the identi¢cation of an additional 1 kb of
MRP3 sequence. The authentic 5P end of MRP3 was
identi¢ed with an adaptor-ligated human liver cDNA
library (Marathon cDNA, Clontech, Palo Alto, CA),
in a PCR using the supplied AP1 primer and a sec-
ond MRP3 speci¢c antisense primer (5P-
CTGGGTACGGGCCCATCTCAGACA-3P, posi-
tion 2486). Three full-length clones termed MRP3
(GenBank No. AF085690) and splice variants desig-
nated MRP3A (GenBank No. AF085691) and
MRP3B (GenBank No. AF085692), both of which
include inserts described and evaluated further be-
low, were ultimately obtained from a human liver
cDNA library by PCR using the primers 5P-CCATG-
GACGCCCTGTGCGGTTCCG-3P (position 32),
and 5P-TCTAACTGGCTCAAACTAGCTGTGAC-
CTTAG-3P (position 4781) encompassing the open
reading frame (subsequently ligated into pCR2.1-
TOPO vector, Invitrogen, Carlsbad, CA). A genomic
MRP3 clone (GenBank No. AC004590), was identi-
¢ed by searching the GenBank database using por-
tions of the cloned cDNA sequence as templates. The
identi¢ed genomic sequence had been part of an un-
characterized genomic clone, sequenced for the Hu-
man Genome Project [10].
In order to determine the relative abundance of
full-length MRP3 and the splice variants (MRP3A
and MRP3B), PCR was carried out on multiple
cDNA libraries derived from human livers (kindly
provided by Dr. F.P. Guengerich, Vanderbilt Uni-
versity, Nashville, TN). Primers were designed to de-
tect MRP3 and a 149 bp insert found in MRP3A/
MRP3B (5P-CAGTCAGCCGCTCACCTATC-3P,
position 3422, and 5P-TCATCCAGTTCAGAGCA-
AAT-3P, position 3711). The presence of this 149
bp sequence at the genomic level was determined
by isolation of a genomic clone using a long-PCR
method. In brief, long PCR (Expand Long Template
PCR System, Boehringer Mannheim, Indianapolis,
IN) was conducted on genomic DNA (extracted
from peripheral lymphocytes) using the primers 5P-
CAGTCAGCCGCTCACCTATC-3P and 5P-TCA-
TCCAGTTCAGAGCAAAT-3P. A single 2 kb PCR
product was obtained, cloned, and sequenced using
the primer 5P-CAGTCAGCCGCTCACCTATC-3P.
The expression of a 55 bp insertion variant in
MRP3B was assessed in human livers using a PCR
containing a forward primer speci¢c to the 55 bp
insert in MRP3B (5P-CTGCTAAACCCTGACC-
CTCTGCGG-3P), and a reverse primer common to
all MRP3 variants (5P-TCCAGCAGCTGCTGCAC-
CACCATC-3P, position 750).
Expression of MRP3 mRNA in human tissues was
determined using Multiple Tissue Northern Blots
(Clontech), following the supplied protocol, using a
32P-labeled MRP3 speci¢c PCR product (1687 bp,
obtained using primers 5P-TGCACCAGGCACT-
GCTGCACAAC-3P, position 3131, and 5P-GAC-
TAGTCTAACTGGCTCA-3P, position 4799) as the
probe. Multiple tissue blots containing approx. 2 Wg
mRNA per lane were prehybridized at 68‡C with
ExpressHyb solution (Clontech), hybridized at the
same temperature with a 32P-labeled MRP3 probe
Fig. 2. Expression of human MRP3. (A) Detection of splice
variants MRP3A in human livers. A PCR product of the size
predicted from the wild-type sequence (309 bp) was found in
4/4 human livers. In 2/4 livers an additional PCR product was
found, indicating the presence of the MRP3A splice variant
(458 bp). (B) The 55 bp splice variant (MRP3B) in human liv-
ers was detected by PCR using a sense primer speci¢c to the 55
bp insert and an antisense primer common to MRP3. A PCR
product of predicted size (153 bp) con¢rming the presence of
MRP3B was found in 4/4 human livers. (C) Northern analysis
of human MRP3 mRNA expression. The 5.1^5.3 kb band is
shown corresponding to the expected size of MRP3 mRNA. L-
Actin expression in the same blots is shown as a positive con-
trol.
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(hybridizing with all variants) and then washed in
0.1USSC and 0.1% SDS at 50‡C. The blots were
then exposed for 2 days.
The open reading frame of the identi¢ed clone
termed MRP3 (GenBank No. AF085690) showed
near total identity to the published sequences of hu-
man MRP3 ([9] and GenBank Nos. Y17151 and
AF083552). We also identi¢ed a clone which con-
tained an additional 149 bp at position 3579 of the
coding sequence (termed MRP3A, GenBank No.
AF085691) leading to a premature stop codon at
nucleic acid position 3717. In addition, a second
splice variant (termed MRP3B, GenBank No.
AF085692) containing the insert seen in MRP3A as
well as an additional 55 bp insert starting at nucleic
acid position 675, leading to a premature stop codon
at position 1533 was found. As discussed below, fur-
ther studies identi¢ed these clones as alternative
splice variants. The predicted sizes for MRP3,
MRP3A, and MRP3B are 1527, 1238 and 510 amino
acids, respectively. The amino acid sequences are
shown in Fig. 1. Depending on the software used
[11,12], 16^18 transmembrane domains were pre-
dicted for the full-length MRP3 (Fig. 1). The
MRP3 protein is 56% identical at the amino acid
level to human MRP1 [13], 44% to human MRP2
(GenBank No. U49248) and 79% to rat mrp3 (or
MLP2, [14]).
PCR for the detection of MRP3 and its splice
variants containing the 149 bp insert revealed that
products of the size predicted from the wild-type
sequence (309 bp; MRP3) were present in 4/4 human
livers (Fig. 2A), while in 2/4 livers, an additional 458
bp PCR product was detected indicating the presence
of the 149 bp insert found in MRP3A and MRP3B
(Fig. 2A). Moreover, the PCR products were se-
quenced after extraction of the respective bands
from the agarose gel (Qiaex II, Qiagen, Valencia,
CA). The sequence of the 309 bp PCR product fully
matched the wild-type sequence (MRP3) and the se-
quence of the 458 bp PCR product was identical to
the MRP3A sequence. The 149 bp insert found in
MRP3A (also present in MRP3B) contains an EcoRI
restriction endonuclease site and EcoRI digests of
MRP3 and MRP3A/MRP3B resulted in the expected
band pattern changes (data not shown). This may be
a convenient method for validating the presence or
absence of this splice variant. The 149 bp sequence
found in MRP3A was present in the genomic clone
DNA and the sequences immediately upstream and
downstream from the 149 bp insert were identical to
those in MRP3. This indicates that alternative splic-
Table 1
Intron-exon organization of human MRP3 from exon 1 to 14
Exon Intron
No. Size (bp) 3P Acceptor 5P Donor No. Size (bp)
1 5PUTR+45 TTCTGG/gtaagg 1 20 850
2 177 ccccag/GACTCC AAGATG/gtcagt 2 693
3 126 tcgcag/GTCCTG ACCATG/gtcagt 3 218
4 138 gcacag/CTGCTG GCAGAG/gtaagg 4 898
5 126 acccag/GGTGAG GACCCT/gtgagt 5 227
6 62 ttctag/AACCCC CACAAA/gtgagt 6 740/685a
7 132 ccccag/GATGGC GGCACG/gtgagg 7 1 554
187a ctccag/GCTGCT
8 192 gaccag/ACACAA GCTCAG/gtctct 8 2 566
9 178 ccacag/CATCCT AGGAAG/gtcagc 9 91
10 162 ctgcag/GCTCTG TGGCAG/gtgact 10 1 041
11 93 cctcag/AACCTA TTCCAG/gtaggt 11 2 308
12 204 gcacag/GTAAAG TTCCTG/gtgagg 12 105
13 147 gctcag/GTGACC ACTCAG/gtaacc 13 420
14 88 ccgtag/GCCAGT CCCCAG/gtctag 14 n.d.
Exon and intron sequences are shown in uppercase and lowercase, respectively.
n.d., not determined.
aThe di¡erent exon and intron sizes are a consequence of alternative splicing described in this paper (MRP3B).
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ing of MRP3 occurs by incomplete removal of this
apparent 149 bp ‘intronic’ sequence, resulting in
MRP3A.
Expression of the 55 bp insert splice variant
(MRP3B) was detected in 4/4 livers (Fig. 2B) by
PCR, using a forward primer speci¢c to the 55 bp
insert in MRP3B, and a reverse primer common to
all MRP3 variants. The identity of the fragment as
the MRP3B insert was veri¢ed through DNA gel
extraction, cloning, and sequencing. We were also
able to identify an as yet uncharacterized genomic
clone derived from human chromosome 17 (Gen-
Bank No. AC004590), which fully matched the 55
bp insert found in MRP3B. Directly downstream
from these 55 bp, an additional 132 bp matching
the common MRP3 sequence were also found. Fur-
ther sequence analysis revealed that this was indeed
the human MRP3 genomic sequence, in agreement
with the fact that human MRP3 had previously been
mapped to chromosome 17 [7]. The 5P and 3P ends of
the 55 bp insert and the adjacent 132 bp sequences as
well as the respective adjacent intronic sequences in-
clude the consensus splicing sequences for a 3P ac-
ceptor site and for a 5P donor site [15,16], thus pro-
viding a mechanism for alternative splicing seen in
MRP3 (Table 1).
Northern analysis showed a band of the expected
size (5.1^5.3 kb) in liver, pancreas, prostate, testis,
small intestine and colon (Fig. 2C). After a 14 day
exposure, a faint band of the same size was also
detected using a blot containing mRNA of di¡erent
regions of human brain (human brain MTN blot II,
Clontech), including cerebral cortex, cerebellum,
frontal lobe, temporal lobe and putamen (data not
shown).
Comparison of the genomic MRP3 sequence and
MRP3 cDNA led to identi¢cation of the 5P-£anking
region (Fig. 3) and a partial exon-intron organization
(from exon 1 to exon 14) of human MRP3 (Table 1).
The total number of exons of MRP3, however, still
has to be determined. Evaluation of the 5P-£anking
region identi¢ed using the HUSAR program Trans-
Fig. 3. 5P-Flanking region of the MRP3 gene. Selected putative binding sites for transcription factors are boxed. Putative transcription
initiation site is indicated by an arrow. The ATG start codon is shown in bold and underlined.
BBAMEM 70858 30-12-98
M.F. Fromm et al. / Biochimica et Biophysica Acta 1415 (1999) 369^374 373
fac [17], failed to reveal the presence of a TATA box.
The lack of a TATA box is also a known feature of
human MRP1, and rat mrp2 [18,19]. Consensus se-
quences for a number of transcription factors includ-
ing AP1, AP2, N-myc, and Sp1 are shown (Fig. 3).
The putative transcription initiation site is based on
that of the cDNA sequence information only, and
not on experimental evidence (Fig. 3). However, it
is likely that the authentic transcription initiation site
is in this region given its close proximity (less than 80
bp) to three near tandem consensus sequences for the
transcription factor, Sp1. Human MRP1 is also
known to have three Sp1 sites near its transcription
initiation site [18]. All intron-exon boundaries con-
form to the consensus splice junction sequences for
eukaryotic cells [15,16]. The 9 bp of the consensus 5P
donor site ((A/C)AG/gt(a/g)agt; uppercase: exon,
lowercase: intron) are conserved in MRP3 in 86,
57, 86, 100, 100, 64, 86, 71 and 50%, respectively.
The 4 bp of the 3P acceptor site ((c/a)ag/(A/G)) are
conserved in 85, 100, 100 and 85%, respectively. The
average size of internal exons is 140 bp, ranging from
62 bp (exon 6) to 204 bp (exon 12). The size of this
partial MRP3 gene spans approx. 33.6 kb.
In summary, we describe for the ¢rst time the
identi¢cation and characterization of human MRP3
alternative splice variants, and its genomic organiza-
tion, including the complete 5P-£anking region and a
major portion of its intron-exon boundaries. In ad-
dition, we found MRP3 mRNA expression not only
in tissues previously identi¢ed as expressing MRP3
[7,9], such as the liver and the intestinal mucosa, but
also in other tissues including the prostate, testis, and
various regions of the brain. Clearly, further studies
are needed to de¢ne the function and the abundance
of MRP3 and its splice variants in normal and tumor
tissues, since available data support the notion of
MRP transporters as important determinants of the
multidrug resistance phenomenon and drug disposi-
tion.
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